pneumonia%20-%20community-acquired
PNEUMONIA - COMMUNITY-ACQUIRED
Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchyma accompanied by symptoms of acute illness and abnormal chest findings.
It is a lower respiratory tract infection acquired in the community within 24 hours to <2 weeks or occurring ≤48 hours of hospital admission in patients who do not meet the criteria for healthcare-associated pneumonia.
It occurs at the highest rates in the very young and the very old.
Potentially life-threatening especially in older adults and those with comorbid disease.

Pneumonia - Community-Acquired Drug Information

Drug Information

Indication: Upper & lower resp tract infections including sinusitis, otitis media, epiglottitis, bacterial pneumonia, ...

Indication: Active immunisation of adults & childn ≥6 mth for prevention of influenza disease caused by 2 influenza...

Indication: Complicated skin & soft tissue infections, community-acquired pneumonia.

Indication: Oral: Lower resp tract infections including bronchitis & pneumonia; skin & soft tissue infections; acu...

Indication: Nosocomial & community-acquired pneumonia including concurrent bacteremia; complicated & uncomplicated...

Indication: Prevention of flu in persons ≥65 yr; adults & childn w/ chronic pulmonary & CV disorders, chronic m...

Indication: Immunisation against pneumococcal disease caused by those pneumococcal types included in the vaccine. Immunoco...

Synflorix
Haemophilus influenzae + pneumococcal polysacchari...

Indication: Active immunisation of infants & childn from 6 wk-5 yr against disease caused by S pneumoniae serotypes 1,...

Indication: Resp; GUT, ophth, skin & soft tissue, biliary tract, GI & ENT infections. Cholecystitis & cholangi...

Indication: Upper & lower resp tract infections, GUT, skin & soft tissue infections, gonorrhoea, acute uncomplicat...

2  /  26
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Elvira Manzano, 12 May 2020
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Rachel Soon, 05 Dec 2020

The Malaysian National Immunisation Programme (NIP) will now include a hexavalent combination DTaP-IPV-HiB-HepB vaccine and a pneumococcal vaccine.

Roshini Claire Anthony, 18 Jun 2020

Endorsement of unproven COVID-19 treatments by high-profile public figures led to a drastic increase in the search and purchase of said treatments in the US, according to a research letter published in JAMA.